News | February 07, 2014

ACC Announces Late-Breaking Trial Presentations

American College of Cardiology Clinical Trial Cath Lab EP Cardiac Diagnostics
February 7, 2014 — Results from several late-breaking clinical trials will be presented during  the American College of Cardiology (ACC) 2014 annual meeting March 29-31. These will be featured during five late-breaking clinical trial sessions. 
 
Joint ACC/JACC Late-Breaking Clinical Trials
Session 451, Saturday, March 29, 8–10 a.m., Hall D (Main Tent)
  • A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
  • The main results of SYMPLICITY HTN-3 renal denervation trial
 
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 402, Sunday, March 30, 8–9:15 a.m., Hall D (Main Tent)
  • Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) Trial
  • The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy - 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
  • Evaluation of the Dual PPAR-?/? Agonist Aleglitazar to Reduce Cardiovascular Events in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus: the AleCardio Trial
  • Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the Nobori Biolimus-Eluting versus Xience/Promus Everolimus-eluting Stent Trial (NEXT)
  • A Phase 3 Double-blind, Randomized Study to Assess the Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin
 
Late-Breaking Clinical Trials III
Session 403, Sunday, March 30, 10:45 a.m.–noon, Hall D (Main Tent)
  • Efficacy And Safety Of Colchicine In Patients With Multiple Recurrences Of Pericarditis: Results Of A Multicenter, Double-blind, Placebo-controlled, Randomized Study (corp-2 Trial)
  • The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
  • One Year Follow-up of the Melody Transcatheter Pulmonary Valve Multicenter Post Approval Study
  • Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
  • Negative High-Sensitive Troponins in the Emergency Department and Risk of Myocardial Infarction
 
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 404, Monday, March 31, 8–9:15 a.m., Hall D (Main Tent)
  • The Impact of Acetyl-Salicylic Acid on Major Arterial and Venous Complications in Patients Undergoing Noncardiac Surgery
  • A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery
  • Steroids in Cardiac Surgery Trial (SIRS)
  • Metformin in Acute Myocardial Infarction
  • Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
 
Late-Breaking Clinical Trials V: [email protected]
Session 405, Monday, March 31, 10:45 a.m.–noon, Hall D (Main Tent)
  • One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
  • A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement - The CHOICE Trial
  • Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention: A Unique Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Designed to Reflect Real-World, Contemporary Practice
  • Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial
  • Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial
 
Late-Breaking Clinical Sessions Deep Dive
Session 406, Monday, March 31, 10:45 a.m.–12:15 p.m., Hall D (Main Tent)
  • Hear key highlights of the LBCTs presented throughout ACC.14 and learn about what it all means for you and your patients
 
For more information: accscientificsession.cardiosource.org

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Overlay Init